Loading
A phase 2 trial of Capecitabine, Oxaliplatin, Disitamab vedotin and Toripalimab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. is a phase 2 interventional study registered as NCT06155383 by RemeGen Co., Ltd., with 90 participants planned, started 2023-11-27 and due to reach its primary completion in 2025-01-31. Interventions recorded: Capecitabine, oxaliplatin, Disitamab Vedotin and Toripalimab.
Shares RemeGen, Disitamab vedotin, HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Oxaliplatin, Capecitabine and the tag pipeline.
Shares RemeGen, Toripalimab, Oxaliplatin, Capecitabine and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.